BioCentury | Apr 11, 2019
Clinical News

Gilead’s NASH combo data suggest benefit, safety

...Gilead combo data are competitive with MRI-PDFF data reported from a much larger trial of MGL-3196...
...a Phase II trial in 125 patients with biopsy-confirmed NASH, 60.3% of patients treated with MGL-3196...
...Investor Concerns” ). Ocaliva and cilofexor are FXR agonists; firsocostat is an ACAC inhibitor; and MGL-3196...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...Madrigal Pharmaceuticals Inc. will report on how their thyroid hormone receptor β agonists, VK2809 and MGL-3196...
...disease processes not targeted by thyroid hormone receptor β agonists. For example, she said since MGL-3196...
...will present data from a Phase II study showing reductions in liver fat produced by MGL-3196...
BioCentury | Oct 5, 2018
Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

...from a Phase II trial of MGL-3196 to treat liver biopsy-confirmed NASH. Those data showed MGL-3196...
...36 (37% vs 8.9% for placebo, p<0.0001) (see "Madrigal Reports 36-Week Phase II Data for MGL-3196...
...combination with selonsertib or placebo daily for 28 days. Madrigal has exclusive, worldwide rights to MGL-3196...
BioCentury | Oct 2, 2018
Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

...from a Phase II trial of MGL-3196 to treat liver biopsy-confirmed NASH. Those data showed MGL-3196...
...combination with selonsertib or placebo daily for 28 days. Madrigal has exclusive, worldwide rights to MGL-3196...
...$78.67; Madrigal lost $2.18 to $210.08; and Viking was off $0.97 to $15.94. Brian Moy GS-9674, px-104 MB07811, VK2809 MGL-3196...
BioCentury | Sep 21, 2018
Clinical News

Viking's VK2809 meets in Phase II for NAFLD

...hormone receptor β. In a Phase II trial to treat liver biopsy-confirmed non-alcoholic steatohepatitis, Madrigal's MGL-3196...
...MGL-3196 achieved a ≥30% reduction in liver fat vs. 18.4% for placebo (p<0.0001) (see “Madrigal's MGL-3196...
...measured by MRI proton density fat fraction (MRI-PDFF) Status: Phase II data Milestone: NA Alicia Parker MB07811, VK2809 MGL-3196...
BioCentury | Sep 18, 2018
Clinical News

Viking gains on Phase II NAFLD data

...$207.30 on Tuesday. In a Phase II trial to treat liver biopsy-confirmed non-alcoholic steatohepatitis, Madrigal's MGL-3196...
...as measured by MRI-PDFF vs. 9.6% for placebo (p<0.0001). Additionally, 60.3% of patients who received MGL-3196...
...VK2809 from Ligand Pharmaceuticals Inc. (NASDAQ:LGND), which was up $12.05 to $265.72 on Tuesday. Alicia Parker MB07811, VK2809 MGL-3196...
BioCentury | Jul 13, 2018
Finance

Pause for politics

...Pharmaceuticals Inc. and infectious disease company Novavax Inc. The former reported liver biopsy data showing MGL-3196...
...China Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Amran Gowani, Senior Editor, Finance & Business Development MGL-3196...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...lead the group. On May 30, the biotech reported liver biopsy data showing lead asset MGL-3196...
...Editor, Finance & Business Development AAVrh74.MHCK7.micro-Dystrophin Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris (Other) ALKS 5461 Intrathecal AVXS-101 MGL-3196...
BioCentury | Jun 13, 2018
Company News

NASH play Madrigal gains on takeout report

...189% since closing at $108.43 on May 30, before it reported liver biopsy data showing MGL-3196...
BioCentury | Jun 12, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

...Phase II NASH readout. Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) gained 145% on May 31 after its MGL-3196...
...significant improvements vs. placebo in disease activity and disease resolution in a Phase II trial. MGL-3196...
Items per page:
1 - 10 of 37